Human VEGF-specific oligonucleotides

Details Human VEGF-specific oligonucleotides Human VEGF-specific oligonucleotides

1995-07-13

1997-06-17

Rories, Charles C. P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 245, 435 6, 435375, A61K 3170, C12N 510, C07H 2100, C12Q 168

Patent

active

056397364

ABSTRACT:
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.

REFERENCES:
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5225326 (1993-07-01), Brenner et al.
patent: 5271941 (1993-12-01), Cho-Chung
Uchida et al., (1995) Antisense Res. & Dev. 5(1):87 (Abstract OP-10).
Nomura et al., (1995) Antisense Res. & Dev. 5(1):91 (Abstract OP-18).
Pierce et al. (1995) Investigative Ophthalmology & Visual Science 36:Abstract 3990.
Smith et al. (1995) Investigative Ophthalmology & Visual Science 36:Abstract 3992.
Michaelson (1948) Trans. Ophthalmol. Soc. U. K. 68:137-180.
Ashton et al. (1954) Br. J. Ophthalmol. 38:397-432.
Am. J. Ophthalmol, (1976) 81:383-396.
Knighton et al. (1983) Science 221:1283-1285.
Senger et al. (1986) Cancer Res. 46:5629-5632.
Folkman et al. (1987) Science 235:442-446.
Ophthalmol. (1991) 98:741-840 (Supplement).
Klagsbrun et al. (1991) Ann. Rev. Physiol. 53:217-239.
Tischer et al. (1991) J. Biol. Chem. 266:11947-11954.
Claffey et al. (1992) J. Biol. Chem. 267:16317-16322.
Plate et al. (1992) Nature 359:845-848.
Plouet et al. (1992) Invest. Ophthalmol. Vis. Sci. 34:900.
Schweiki et al. (1992) Nature 359:843-845.
Adamis et al. (1993) Biochem. Biophys. Res. Commun. 193:631-638.
Adamis et al. (1993) Invest. Ophthalmol. Vis. Sci. 34:1440.
Kim et al. (1993) Nature 362:841-844.
Miller et al. (1993) Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, p. 760.
Aiello et al. (1994) New Eng. J. Med. 331:1480-1487.
Aiello et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1868.
Bressler et al., Principles and Practices of Ophthalmology (eds. Albert and Jakobiac), W.B. Saunders Co., Philadelphia, PA) (1994) vol. 2.
Foster in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., New York (1994) pp. 1994-1995.
Pierce et al. (1994) Int. Ophth. Clinics 34:121-148.
Simorre-Pinatel et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:3393-3400.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1442.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:101-111.
Focus (Jan. 6, 1995).
Ophthalmology World News (1995) p. 26.
Ophthalmology Times (Jan. 16-22, 1995).
Pierce et al. (1995) Proc. Natl. Acad. Sci. (USA) 92:905-909.
Monacci et al. (1993) American Journal Of Physiology 264:c995-c1002.
Garrido et al. (1993) Growth Factors 8:109-117.
E. Uhlmann et al. Chem Rev. 90(4) (Jun. 1990) 543-84.
W. James Antivir. Chem. & Chemother. 2(4) ('91) 191-214.
J. Milligan et al. J. Med. Chem. 36(14) (Jul. 9, 1993) 1923-37.
C. Stein et al. Science 261 (Aug. 20, 1993) 1004-12.
B. Tseng et al. Cancer Gene Therapy 1(1) (Mar. 1994) 65-71.
P. Westermann et al. Biomed. Biochim. Acta 48(1) ('89) 85-93.
J. Wetmer Crit. Rev. Biochem. Mol. Biol. 26 (3/4) (91) 227-59.

Affiliated with

Also associated with

Rating

Human VEGF-specific oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human VEGF-specific oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human VEGF-specific oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2157845